A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects

Trial Profile

A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Inarigivir soproxil (Primary) ; Tenofovir alafenamide (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 20 Jun 2018 Treatment arms has been changed from 3 to 4. Planned patient number has increased.
    • 20 Jun 2018 Planned number of patients changed from 70 to 90.
    • 03 May 2018 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top